The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. A strong Q1 performance set the tone, but ...
Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday. The number of bullish hedge fund bets decreased by 6 lately.
Unsure of the value of our premium account? In a report released today, Jay Olson from Oppenheimer assigned a Hold rating to ACADIA Pharmaceuticals (ACAD), with a price ... ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Take the temperature and While our free users beat the market by 7% per quarter, last quarter, our premium users have Any opinions, news, research, analyses, prices, or other information offered by AIStockFinder is provided as general market commentary, and does not constitute investment advice. The biopharma's stock is …
The stock was sold at an average price of $49.21, for a total value of $333,151.70. ACADIA PHARMACEUTICALS INC stock price forecast for further price development down to -3.44% (time horizon: 1 day) and price target of 54.14 USD. Investors who are in the know were selling. Positive news sentiment.
The company presently has an average rating of “Buy” and a consensus price target of $57.06.ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Thursday, May 7th.
Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock.
Investors can use this forecasting interface to forecast ACADIA Pharmaceuticals historical stock prices and determine the direction of ACADIA Pharmaceuticals future trends based on various well-known forecasting models. At ACADIA, we are passionate about improving the lives of patients with central nervous system (CNS) disorders. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA. FY2021 Earnings Forecast for ACADIA Pharmaceuticals Inc.
Weiss Multi Strategy Advisers LLC now owns 95,386 shares of the biopharmaceutical company’s stock valued at $4,030,000 after purchasing an additional 386 shares in the last quarter. Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ladenburg Thalmann Financial Services Inc. raised its position in ACADIA Pharmaceuticals by 1.9% during the fourth quarter. ACADIA Pharmaceuticals had a negative net margin of 64.99% and a negative return on equity of 39.40%.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.
Finally, Royal Bank of Canada cut their price target on ACADIA Pharmaceuticals from $61.00 to $55.00 and set an “outperform” rating on the stock in a research note on Tuesday. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 11th expiration. Accused of Misleading Shareholders. Our latest prediction for ACADIA Pharmaceuticals, Inc.'s stock price was made on the Weiss Multi Strategy Advisers LLC raised its position in ACADIA Pharmaceuticals by 0.4% during the first quarter. …
Ladenburg Thalmann Financial Services Inc. now owns 23,445 shares of the biopharmaceutical company’s stock valued at $987,000 after purchasing an additional 427 shares in the last quarter. Stifel Nicolaus raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $41.00 to $71.00 in a research note on Monday, July 6th. The book value per share is 2.12$
However, solely looking at the historical price movement is usually misleading. BidaskClub raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, June 17th. Advisor Group Inc. now owns 3,577 shares of the biopharmaceutical company’s stock valued at $153,000 after purchasing an additional 440 shares in the last quarter. A number of other research analysts also recently weighed in on the company.
The most recent analyst activity for ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] stock was on April 16, 2020, when it was Initiated with a Buy rating from Jefferies, which also raised its 12-month price target on the stock to $60.
Shares of mid-cap drugmaker Acadia Pharmaceuticals (NASDAQ:ACAD) rose by as much as 13% in pre-market trading today.